- Home
- ALEX vs RCKT Comparison
ALEX vs RCKT Comparison
Compare ALEX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEX
- RCKT
- Stock Information
- Founded
- ALEX 1870
- RCKT 1999
- Country
- ALEX United States
- RCKT United States
- Employees
- ALEX N/A
- RCKT N/A
- Industry
- ALEX Real Estate Investment Trusts
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- ALEX Real Estate
- RCKT Health Care
- Exchange
- ALEX Nasdaq
- RCKT Nasdaq
- Market Cap
- ALEX 1.4B
- RCKT 1.4B
- IPO Year
- ALEX N/A
- RCKT N/A
- Fundamental
- Price
- ALEX $19.30
- RCKT $13.98
- Analyst Decision
- ALEX Strong Buy
- RCKT Strong Buy
- Analyst Count
- ALEX 4
- RCKT 9
- Target Price
- ALEX $21.67
- RCKT $53.22
- AVG Volume (30 Days)
- ALEX 276.2K
- RCKT 744.0K
- Earning Date
- ALEX 10-24-2024
- RCKT 11-07-2024
- Dividend Yield
- ALEX 4.62%
- RCKT N/A
- EPS Growth
- ALEX N/A
- RCKT N/A
- EPS
- ALEX 0.61
- RCKT N/A
- Revenue
- ALEX $230,949,000.00
- RCKT N/A
- Revenue This Year
- ALEX N/A
- RCKT N/A
- Revenue Next Year
- ALEX $2.08
- RCKT $411.05
- P/E Ratio
- ALEX $23.54
- RCKT N/A
- Revenue Growth
- ALEX 1.30
- RCKT N/A
- 52 Week Low
- ALEX $15.53
- RCKT $13.80
- 52 Week High
- ALEX $20.30
- RCKT $32.53
- Technical
- Relative Strength Index (RSI)
- ALEX 53.63
- RCKT 27.71
- Support Level
- ALEX $19.01
- RCKT $16.65
- Resistance Level
- ALEX $19.97
- RCKT $17.83
- Average True Range (ATR)
- ALEX 0.33
- RCKT 0.89
- MACD
- ALEX 0.03
- RCKT -0.27
- Stochastic Oscillator
- ALEX 53.47
- RCKT 4.12
About ALEX Alexander & Baldwin Inc. REIT Holding Company
Alexander & Baldwin Inc operates in the real estate sector. It functions through two segments namely Commercial Real Estate and Land Operations. The Commercial Real Estate segment owns and manages retail, industrial spaces and also urban ground leases in Hawaii, thereby accounting for majority of the company's revenue. The Land Operations segment actively manages the company's land and real estate-related assets and makes optimum utilization of these assets. Geographically, the activities are carried out across the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.